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Murine ‘‘inflammatory’’ and ‘‘patrolling’’ monocytes have specific functional specializations. In this issue of
Immunity, Cros et al. (2010) characterize CD14+ and CD14dimCD16+ monocyte subpopulations as the human
‘‘inflammatory’’ and ‘‘patrolling’’ monocytes that, similarly to their mouse counterparts, are characterized by
distinct functional properties.Peripheral bloodmonocytes play a critical
role in the host response, exerting many
different functions. These include produc-
tion of various cytokines, antitumor and
antimicrobial effects, as well as activation
of lymphocytes. Because of the large
panel of functions ascribed tomonocytes,
it has been previously suggested that
different subpopulations of human mono-
cytes may be found, with distinct pheno-
type and function. In 1996, Ziegler-Heit-
brock suggested that the differential
expression of CD14 and CD16 on human
monocytes could define at least two
subsets of monocytes with distinct func-
tional properties and that this could lead
to new insights in the pathophysiology of
inflammatory diseases (Ziegler-Heit-
brock, 1996). Early work demonstrated
that the percentage of monocytes
expressing both CD14 and CD16, in
contrast to those expressing solely
CD14, was higher in patients with sepsis
and cancer, which prompted the need to
understand the role of these monocyte
subpopulations in health and disease (Fin-
gerle et al., 1993). Recently, an official
nomenclature has been proposed for
these cells that has been approved by
the Nomenclature Committee of the Inter-
national Union of Immunological Societies
(NC-IUIS). This nomenclature defines
three typesofmonocytes: classicalmono-
cytes (CD14++CD16), intermediate
monocytes (CD14++CD16+), and nonclas-
sical monocytes (CD14+CD16++) (Ziegler-
Heitbrock et al., 2010). In order to dispel
some possible confusion arising from
this, we should underline that the literature
often characterizes monocyte subsets
as CD14+CD16 (that can be viewed in
line of the above proposed nomenclature
as CD14++CD16) and CD14dimCD16+
(the equivalent of CD14+CD16+).An important step toward under-
standing the function of monocyte
subpopulations was represented by the
description of two distinct populations of
‘‘inflammatory’’ and ‘‘patrolling’’ mono-
cytes in mice (Geissmann et al., 2003).
Murine inflammatorymonocytes are char-
acterized by the expression of the granu-
locyte differentiation antigen-1 (Gr1+)
marker and are specialized in tumor
necrosis factor-a (TNFa), reactive oxygen
species (ROS), and nitric oxide (NO)
production, being implicated in host
defense during infections. In contrast,
murine Gr1 monocytes patrol the blood
vessels and are mainly associated with
tissue repair (Geissmann et al., 2003),
while their role in response to infections
has not been elucidated. The description
of these murine monocyte subpopula-
tions opened new avenues in our under-
standing of monocyte heterogeneity, and
their differential function has raised the
hope of identifying novel, and more
specific, therapeutic approaches in infec-
tion and inflammation. However, in order
to be able to translate these discoveries
into novel therapies in humans, several
fundamental questions remained to be
answered: which human monocyte
subpopulations are the functional homo-
logs of murine ‘‘inflammatory’’ and
‘‘patrolling’’ monocytes? And if such
subpopulations of human monocytes
exist, how can they be characterized
phenotypically and functionally? The
study by Cros et al. in the present issue
of Immunity represents a crucial first
step toward achieving these aims.
The first important contribution of the
study of Cros et al. is represented by the
description of the human monocyte
homologs of the murine ‘‘inflammatory’’
and ‘‘patrolling’’ monocytes. Using anImmunity 33, Seelegant combination of expressionpattern
studies, phenotypic characterization of
surface markers, and functional transfer
studies in Rag/ gc/ Cx3cr1gfp mice in
which only circulating monocytes express
the green fluorescence protein, the
authors demonstrated that both human
CD14+CD16 and CD14+CD16+ mono-
cytes have inflammatory properties remi-
niscent of the murine Gr1+ monocytes,
while CD14dimCD16+ monocytes display
patrolling properties similar to those of
murine Gr1 monocytes. The identifica-
tion of CD14dimCD16+ monocytes (the
nonclassical monocytes in the novel
nomenclature) as the human ‘‘patrolling’’
monocytes represents a major step
toward understanding functional differen-
tiation of human monocyte populations.
Somewhat less clear is the functional
differentiation between CD14+CD16 (the
equivalent of the classical CD14++CD16
monocytes in the nomenclature of the
NC-IUIS) and CD14+CD16 (the equiva-
lent of the intermediate CD14++CD16+)
monocytes. Both these subsets of inflam-
matory monocytes responded with cyto-
kine production upon stimulation with
bacterial stimuli such as the Toll-like
receptor-4 (TLR4) agonist lipopolysac-
charide (LPS) or the TLR2 agonist
Pam3Cys, although differences were
observed in the panel of cytokines
released by either the classical or inter-
mediate subpopulations (Cros et al.,
2010). In contrast, and not totally unex-
pected considering the role of coreceptor
of CD14 for TLR4 and TLR2 (Wright et al.,
1990), stimulation of the CD14dimCD16+
monocytes with bacterial stimuli elicited
an attenuated cytokine response.
A second important contribution of the
study of Cros et al. is the discovery of
a novel immunological function ofptember 24, 2010 ª2010 Elsevier Inc. 289
Figure 1. Phenotypic and Functional Differences between Human Monocyte Subsets
CD14+CD16+ and CD14+CD16 monocytes produce proinflammatory cytokines in response to stimuli
that are recognized by TLR4 and TLR2 in a p38 MAPK-dependent manner. CD14 is a coreceptor of
TLR4 and TLR2 and plays a significant role in these signaling pathways. On the other hand, CD14dimCD16+
monocytes lack CD14, and TLR2 and TLR4 stimulation by bacterial ligands does not result in proinflam-
matory cytokine production. However, CD14dimCD16+ monocytes produce proinflammatory cytokines in
response to viruses in a TLR7- and TLR8-MEK1-dependent pathway. In contrast to CD14+monocytes, the
CD14dimCD16+monocytes patrol the vascular endothelium in an LFA-1 dependentmanner. LPS, lipopoly-
saccharide; TLR, Toll-like receptor; LFA-1, Lymphocyte function-associated antigen 1; TNF, Tumor
necrosis factor; IL, Interleukin; ssRNA, single-stranded RNA.
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tolerance of CD14dimCD16+ monocytes
toward bacterial stimuli, a major surprise
was obtained when these cells were stim-
ulated with viral stimuli: they release high
amounts of proinflammatory cytokines in
a TLR7- and TLR8-dependent, as well as
MyD88-dependent manner. These find-
ings represent an important novel con-
ceptual advance, and they open an
unexpected perspective in the function
of CD14dimCD16+ monocytes, which, in
addition to their patrolling and repair activ-
ities, may have an important role in anti-
viral immunity. The differential intracellular
molecular pathways in human CD14+ and
CD14dimCD16+ monocytes have also
been deciphered: cytokine production
induced by bacterial and viral stimuli is
mediated through p38 mitogen-activated
protein kinase (MAPK) in inflammatory
CD14+ monocytes, while phosporylation
of meiotic kinase-1 (MEK1, Erk) by TLR7-
and TLR8-dependent stimulation induces
cytokine production in CD14dimCD16+
monocytes (Figure 1).290 Immunity 33, September 24, 2010 ª2010But are CD14dimCD16+ cells really
monocytes? This question was
addressed in the study by the use of
cells from patients that are deficient in
the common cytokine receptor gamma
chain (gc). As a result of the defect,
these patients lack all lymphoid lineages.
The authors demonstrated that the
CD14dimCD16+ monocytes are not
lymphoid and that they are genetically
distinct from natural killer (NK) cells,
a cell population that also expresses
CD16 and HLA-DR. In addition, they
showed that nonclassical monocytes do
not have the capacity to present antigens
to T cells, strongly suggesting that they
are not a particular type of dendritic cell
(antigen-presenting cell) population.
Less clear answers were provided by
the attempts of the authors to demon-
strate the clinical relevance of these find-
ings. Systemic lupus erythematosus (SLE)
is a prototypical autoimmune disease
that is characterized by immune-complex
pathology. Immune complexes in SLE
contain nucleic acids, and therefore,Elsevier Inc.Cros et al. hypothesized that
CD14dimCD16+ monocytes could play
a role in SLE by inducing inflammation in
response to immune complexes. They
incubated nonclassical monocytes with
sera from healthy volunteers or SLE
patients and found that nonclassical
monocytes indeed produced a proinflam-
matory cytokine profile in response to the
sera of SLE patients, which was depen-
dent on the nucleic acid-containing im-
munocomplexes. Whether similar differ-
ential responses may also be obtained in
classical CD14+ monocytes and which
mechanism is responsible for stimulation
of non-classical CD14dimCD16+ mono-
cytes by patient sera was not evaluated.
This study is an important step in under-
standing the heterogeneity in phenotype
and function of humanmonocyte subpop-
ulations, yet important questions remain.
First, a relevant question that still needs
to be elucidated concerns the origin of
the various monocyte subpopulations:
are they end-stages of different paths of
differentiation of a common precursor, or
do they represent subsequent maturation
stages in a common path of differentia-
tion? Second, andmaybe evenmore rele-
vant, how rigid is the phenotypic and
functional status of these monocyte
subpopulations: are they in a final stage
of differentiation excluding the ability to
‘‘switch’’ from one subpopulation to
another, or are they characterized by
a certain level of plasticity that allows
them tometamorphose from one subpop-
ulation into another in certain physiolog-
ical or pathological conditions? Finally,
and this will be crucial for the clinical
translation of these findings, what are
the differential roles of ‘‘inflammatory’’
and ‘‘patrolling’’ monocytes in various
human pathologies?
Human CD14+CD16+ monocytes have
been suggested to play an important
role in several inflammatory conditions,
such as rheumatoid arthritis and athero-
sclerosis (Baeten et al., 2000; Schlitt
et al., 2004), as well as in bacterial infec-
tions (Blumenstein et al., 1997; Fingerle
et al., 1993; Herra et al., 1996). There are
several experimental murine models that
closely mimic these human diseases,
making it possible to study the relation-
ship between the monocyte subpopula-
tions and the pathophysiology of these
conditions. The findings provided in the
study by Cros et al. make it possible to
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diate, and nonclassical monocytes in
thesemodels, potentially identifying novel
targets for therapy.
Over the recent years, an increasing
amount of knowledge has been gained
in the field of monocyte subpopulations.
Although there is still much to be learned,
the study of Cros et al. brings us one step
closer to a better understanding of mono-
cytes in health and disease, which poten-
tially paves the way for developing new
immunomodulatory therapies.
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In this issue of Immunity, Omatsu et al. (2010) provide new information on the CXCL12 abundant reticular
(CAR) cells that support hematopoietic stem cells and lymphoid progenitors in bone marrow. CAR cells
can convert to adipocytes and osteoblasts, additional cells known to regulate hematopoiesis.Hematopoietic stem cells (HSCs) sustain
blood formation throughout life and
their integrity depends on residence in
specialized niches within bone marrow.
However, there are considerable tech-
nical problems associated with sectioning
lipid-rich, bone-encapsulated tissue while
preserving distinctive niche markers and
unambiguously identifying HSCs. For
those and other reasons, precise informa-
tion about the cellular and molecular
composition of those niches has been
difficult to obtain. Fortunately, those
hurdles have been overcome, and a new
picture is emerging about how the factory
that marrow represents can adapt to
circumstances.
The CXCL12 chemokine (also known as
SDF-1) is essential for the initial coloniza-
tion, retention, and support of HSCs andearly B lymphocyte lineage cells in bone
marrow. Identification of CXCL12 abun-
dant reticular (CAR) cells as a major
source of this factor was previously
achieved with CXCL12-GFP (green fluo-
rescent protein) knockin mice (Sugiyama
et al., 2006). CAR cells are scattered in
the extravascular regions of marrow,
with some near the endosteum and others
surrounding venous sinusoids (Figure 1).
HSCs and some, but not all, lymphoid
progenitors physically associate with
CAR cells. Omatsu et al. (2010) now
obtain new information about their func-
tion with CXCL12-DTR (diphtheria toxin
receptor)-GFP knockin animals. Although
GFP+ CAR cells can be imaged when the
mice are untreated, they are effectively
depleted within 2 days of injection of dip-
theria toxin (DT). Control chimeric mouseexperiments showed that hematopoietic
cells are not directly affected by DT.
Importantly, numbers of spindle-shaped
N-cadherin+ CD45 osteoblastic cells
and sinusoidal endothelial cells were not
reduced. HSCs have previously been
shown to physically associate with both
of these two cell types (Zhang and Li,
2008; Kiel and Morrison, 2008).
Selective CAR cell ablation caused an
approximate 50% reduction in HSC
numbers and much greater depletion of
hematopoietic progenitors. Although it is
unclear whether that resulted frommobili-
zation out of themarrow, HSCs retained in
that site had unique properties. That is,
they were smaller in size and had reduced
RNA and less cell cycle promoting gene
expression. This suggests that they were
even more quiescent than is typical forptember 24, 2010 ª2010 Elsevier Inc. 291
